Position in KALV
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$1,105,137
+$218,502 QoQ
Shares Held
54,900
0.0% QoQ
Ownership
0.103%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#75
of 182 holders
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Swiss National Bank holds $1,640,558,253 across 148 Biotechnology names. KALV ranks #127 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
744,600 | $332,493,684 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
303,140 | $234,218,089 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
387,720 | $128,284,916 | |
| 4 | INSM |
INSMED Inc
|
625,912 | $102,349,130 | |
| 5 | RPRX |
Royalty Pharma plc
|
1,191,100 | $57,137,067 | |
| 6 | INCY |
Incyte Corp
|
489,774 | $46,097,528 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
425,431 | $41,373,164 | |
| 8 | MRNA |
Moderna, Inc.
|
696,100 | $35,361,880 |
All Filings in KALV
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,105,137 | 54,900 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $886,635 | 54,900 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $590,730 | 48,500 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||